WT1 and acute lymphoblastic leukemia: In addition, Zhao et al.39 reported that the relapse rate of ALL patients who had one positive WT1 result after allo-HSCT was 63.9%, and the sensitivity and specificity of WT1 was 62.2% and 90.6%, respectively, for indicating ALL relapse in allo-HSCT recipients.